S. Etude-de-persistance-la and L. La, 68 a. La Short-Term Persistence Substudy (STPS), p.68

.. Le-coût-du-zona-et-des-douleurs-post-zostériennes and E. Etude, 78 a, p.80

B. Rentier and C. , Sadzot-Delvaux «Le virus de la varicelle et du zona dans le système nerveux : retraite silencieuse ou guérilla permanente ?» Virologie n°4, pp.207-216, 2000.

. Zerboni, Molecular mechanisms of varicella zoster virus pathogenesis, Nature Reviews Microbiology, vol.86, issue.3, pp.197-210, 2014.
DOI : 10.1038/nrmicro3215

D. Floret, «Varicelle de l'enfant» chez EMC Pédiatrie/Maladies infectieuses, pp.4-310, 2006.

. Agence-de-la-santé-publique-du, Canada. www.santepublique.gc.ca. Virus varicelle zona fiche technique santé-sécurité : agents pathogènes

J. Bonnetblanc, «Item 84 -Infections à herpès virus de l'enfant et de l'adulte immunocompétents : varicelle et zona» chez Annales de dermatologie et de vénérologie, 2008.

J. I. Cohen, «VZV : molecular basis of persistence (latency and reactivation)» chez Human Herpesviruses : Biology, Therapy, and immunoprophylaxis, 2007.

J. Pr and . Gaudelus, Hôpital Jean Verdier, «fmp-usmba,» http://www.fmpusmba.ac.ma/umvf/UMVFmiroir/campus-numeriques/campus- pediatrie

F. Evrard, «La varicelle» Cahier de la puericultrice n°249, pp.31-34, 2011.

A. Weinberg and M. J. Levin, «VZV T cell-mediated immunity» chez Varicella-Zoster Virus : Current Topics in Microbiology and immunology, pp.341-358, 2010.

H. Tolou, https://www.mesvaccins.net/web/news/5629- nouvelles-recommandations-vaccinales-de-l-organisation-mondiale-de-la-sante-contre-lavaricelle-et-le-zona

«. Invs and . Du, Conseil supérieur d'hygiène publique de France (section des maladies transmissibles) relatif à la vaccination contre la varicelle, pp.127-156, 2004.

S. Buchbinder, Herpes Zoster and Human Immunodeficiency Virus Infection, Journal of Infectious Diseases, vol.166, issue.5, pp.1153-1156, 1992.
DOI : 10.1093/infdis/166.5.1153

A. Arvin, Selective Impairment of Lymphocyte Reactivity to Varicella-Zoster Virus Antigen among Untreated Patients with Lymphoma, Journal of Infectious Diseases, vol.137, issue.5, pp.531-540, 1978.
DOI : 10.1093/infdis/137.5.531

M. Onozawa, Relationship between Preexisting Anti-Varicella-Zoster Virus (VZV) Antibody and Clinical VZV Reactivation in Hematopoietic Stem Cell Transplantation Recipients, Journal of Clinical Microbiology, vol.44, issue.12, pp.41-43, 2006.
DOI : 10.1128/JCM.01312-06

A. Hata, Use of an Inactivated Varicella Vaccine in Recipients of Hematopoietic-Cell Transplants, New England Journal of Medicine, vol.347, issue.1, pp.26-34, 2002.
DOI : 10.1056/NEJMoa013441

R. Hope-simpson, The nature of herpes zoster: a long-term study and a new hypothesis», Proc R Soc Med, vol.58, pp.9-20, 1965.

A. Weinberg, Varicella???Zoster Virus???Specific Immune Responses to Herpes Zoster in Elderly Participants in a Trial of a Clinically Effective Zoster Vaccine, The Journal of Infectious Diseases, vol.200, issue.7, pp.1068-1077, 2009.
DOI : 10.1086/605611

A. Hayward and M. Herberger, Lymphocyte responses to varicella zoster virus in the elderly, Journal of Clinical Immunology, vol.149, issue.2, pp.174-178, 1987.
DOI : 10.1007/BF00916011

S. K. Mehta, Multiple latent viruses reactivate in astronauts during Space Shuttle missions, Brain, Behavior, and Immunity, vol.41, pp.210-217, 2014.
DOI : 10.1016/j.bbi.2014.05.014

N. Peter, Uchakin et al, «Fatigue in Medical Residents Leads to Reactivation of Herpes Virus Latency» Interdisciplinary Perspectives on Infectious Diseases, 2011.

M. N. Oxman, A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults, New England Journal of Medicine, vol.352, issue.22, pp.71-84, 2005.
DOI : 10.1056/NEJMoa051016

I. Frazer and M. Levin, Paradigm shifting vaccines: prophylactic vaccines against latent varicella-zoster virus infection and against HPV-associated cancer, Current Opinion in Virology, vol.1, issue.4, pp.268-279, 2011.
DOI : 10.1016/j.coviro.2011.07.007

. Pinchinat, Similar herpes zoster incidence across Europe: results from a systematic literature review, BMC Infectious Diseases, vol.127, issue.68, 2013.
DOI : 10.1017/S0950268801005921

A. Ann, «Aging, Immunity, and the Varicella?Zoster Virus», N Engl J Med, issue.2, 2005.

. Pr and . Bernard-de-wazieres, «Le zona : diagnostic, évolution, modalités de prise en charge et vaccination» Repères en Gériatrie, p.124, 2013.

K. Schmader, Herpes Zoster and Postherpetic Neuralgia in Older Adults, Clinics in Geriatric Medicine, vol.23, issue.3, pp.615-632, 2007.
DOI : 10.1016/j.cger.2007.03.003

R. H. Kenneth and E. Schmader, «Natural history and treatment of herpes zoster», The Journal of Pain, vol.9, issue.1, pp.3-9, 2008.

J. Léger and K. Viala, Herpes virus, virus varicelle-zona (VZV), cytomégalovirus (CMV), mononucléose infectieuse, diphtérie» chez Neuropathies périphériques, polyneuropathies et mononeuropathies multiples, pp.203-211, 2005.

D. Bouhassira, Patient perspective on herpes zoster and its complications: An observational prospective study in patients aged over 50 years in general practice, Pain, vol.153, issue.2, pp.342-349, 2012.
DOI : 10.1016/j.pain.2011.10.026

S. Mathis and J. Gil, Le zona et ses complications neurologiques, Revue Neurologique, vol.162, issue.8-9, pp.879-887, 2006.
DOI : 10.1016/S0035-3787(06)75096-2

G. Pr, P. A. Berrut, P. N. Serrie, . Attal, J. Dr et al., Le zona et ses complications douloureuses, constats et rapports d'experts, 2014.

S. Durga, «Incidence of herpes zoster ophtalmicus:results from the Pacific Ocular Inflammation Study» Ophthalmology, pp.451-456, 2013.

M. Stowasser, J. Cameron, and W. Olivier, «Diaphragmatic paralysis following cervical herpes zoster», Med J Aust, vol.153, pp.555-556, 1990.

R. Johnson and T. Whitton, Management of herpes zoster (shingles) and postherpetic neuralgia, Expert Opinion on Pharmacotherapy, vol.0, issue.4, pp.551-559, 2004.
DOI : 10.1097/00002508-200009000-00005

J. Kang, J. Ho, and Y. Chen, «Increased risk of stroke after a herpes zoster attack. A populationbased follow-up study» Stroke, pp.3443-3451, 2009.

J. Gnann, . Jr, R. Whitley, and . Zoster», Herpes Zoster, New England Journal of Medicine, vol.347, issue.5, pp.340-346, 2002.
DOI : 10.1056/NEJMcp013211

. Dworkin, «Recommendations for the Management of Herpes Zoster» Clinical Infectious Diseases, pp.1-26, 2007.

R. Dworkin and R. Portenoy, Proposed classification of herpes zoster pain, The Lancet, vol.343, issue.8913, p.1648, 1994.
DOI : 10.1016/S0140-6736(94)93106-2

Y. Hoon-jeon, «. Zoster, and P. Neuralgia, Practical Consideration for Prevention and Treatment», Korean J Pain, vol.28, pp.3-177, 2015.

. Drolet, «Predictors of posthepetic neuralgia among patients with herpes zoster : a prospective study», The Journal of Pain, vol.3, issue.3, pp.1-11, 2010.

. Opstelten, Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: Prospective prognostic study, Pain, vol.132, pp.52-59, 2007.
DOI : 10.1016/j.pain.2007.02.004

P. Coplan, Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: Adaptation of the brief pain inventory, The Journal of Pain, vol.5, issue.6, pp.344-356, 2004.
DOI : 10.1016/j.jpain.2004.06.001

R. Melzack and . Mcgill, Pain Questionnaire» chez Pain Measurement and Assessment, pp.41-47, 1983.

A. Leplège, M. Mesbah, and P. Marquis, «Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: the MOS SF-36 (version 1.1)» Rev Epidemiol Sante Publique, pp.371-379, 1995.

B. Gandek and J. Ware, Aaronson NK et al «Cross-validation of item selection and scoringfor the SF-12 Health Survey in nine countries : results from the IQOLA Project InternationalQuality of, Life Assessment» J Clin Epidemiol, issue.11, pp.51-71, 1998.

J. Brazier, N. Jones, and P. Kind, Testing the validity of the Euroqol and comparing it with the SF-36 health survey questionnaire, Quality of Life Research, vol.40, issue.3, pp.169-180, 1993.
DOI : 10.1007/BF00435221

A. Zigmond and R. Snaith, «The Hospital Anxiety and Depression Scale» Acta Psychiatr Scand, pp.361-370, 1983.

. Schmader, The Impact of Acute Herpes Zoster Pain and Discomfort on Functional Status and Quality of Life in Older Adults, The Clinical Journal of Pain, vol.23, issue.6, pp.490-496, 2007.
DOI : 10.1097/AJP.0b013e318065b6c9

J. Katz, E. Cooper, and R. Walther, Acute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life, Clinical Infectious Diseases, vol.39, issue.3, pp.342-348, 2004.
DOI : 10.1086/421942

T. Weinke, A. Edte, S. Schmitt, and K. Lukas, Impact of herpes zoster and post-herpetic neuralgia on patients??? quality of life: a patient-reported outcomes survey, Journal of Public Health, vol.82, issue.Suppl 2, pp.367-374, 2010.
DOI : 10.1007/s10389-010-0323-0

URL : https://hal.archives-ouvertes.fr/hal-00535311

M. Drolet, M. Brisson, and K. Schmader, The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study, Canadian Medical Association Journal, vol.182, issue.16, pp.1731-1737, 2010.
DOI : 10.1503/cmaj.091711

D. Bouhassira, Patient perspective on herpes zoster and its complications: An observational prospective study in patients aged over 50 years in general practice, Pain, vol.153, issue.2, pp.342-349, 2012.
DOI : 10.1016/j.pain.2011.10.026

C. Rabaud, «Un traitement antiviral précoce ne prévient pas toutes les douleurs associées au zona» Médecine et maladies infectieuses, pp.461-466, 2013.

Q. Li, N. Chen, and Y. J. , «Antiviral treatment for preventing postherpetic neuralgia» Cochrane database Syst Rev, 2009.

P. Lang and N. , Ferahta, «Recommandations pour le traitement et la prévention du zona et des douleurs associées chez la personne âgée» Rev Med Interne, 2015.

J. Berry and K. Petersen, «A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster» Neurology, pp.444-447, 2005.

C. Jensen-dahm, «Effect of a single dose of pregabalin on herpes zoster pain» Trials, p.55, 2011.

J. Edelsberg, C. Lord, and G. Oster, «Systematic Review and meta-analysis of efficacy, safety and tolerability data from randomized controlled trials of drugs used to treat postherpetic neuralgia» Ann Pharmacother, pp.1483-90, 2011.

P. Hansson and A. Dickenson, Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies, Pain, vol.113, issue.3, pp.251-254, 2005.
DOI : 10.1016/j.pain.2004.10.007

T. Schmid, S. Pautex, and P. Lang, «Douleurs zostériennes et post-zostériennes chez la personne âgée : analyse des évidences pour une prise en charge adaptée» Rev Med Suisse, pp.1374-1382, 2012.

R. Moore, P. Wiffen, and S. Derry, et al «Gabapentin for chronic neuropathic pain and fibromyalgia in adults», Cochrane Database Syst Rev, issue.3, 2011.

R. Moore, Pregabalin for acute and chronic pain in adults, Cochrane Database Syst Rev, vol.17, issue.5, 2009.
DOI : 10.1002/14651858.CD007076.pub2

G. Irving, M. Jensen, M. Cramer, J. Wu, Y. Chiang et al., Efficacy and Tolerability of Gastric-retentive Gabapentin for the Treatment of Postherpetic Neuralgia, The Clinical Journal of Pain, vol.25, issue.3, pp.185-192, 2009.
DOI : 10.1097/AJP.0b013e3181934276

N. Attal, EFNS guidelines on pharmacological treatment of neuropathic pain, European Journal of Neurology, vol.32, issue.2, pp.1113-88, 2010.
DOI : 10.1053/eujp.2001.0316

S. Derry, «Topical capsaicin for chronic neuropathic pain in adults» Cochrane Database Syst Rev, 2009.

L. Xiao, «Subcutaneous injection of botulinium toxin a is beneficial in postherpetic neuralgia», Clin Drug Investig, vol.11, pp.1827-1860, 2010.

. Schmader, «Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50?59 Years» Clinical Infectious Diseases, pp.922-928, 2012.

A. and «. Des-médicaments»-http, ansm.sante.fr/Activites/Surveillance-des- medicaments/Surveillance-des-medicaments

B. Kerzner, A. Murray, and E. Cheng, Safety and Immunogenicity Profile of the Concomitant Administration of ZOSTAVAX and Inactivated Influenza Vaccine in Adults Aged 50 and Older, Journal of the American Geriatrics Society, vol.25, issue.10, pp.1499-1507, 2007.
DOI : 10.1111/j.1532-5415.2007.01397.x

C. Macintyre, T. Egerton, and M. Mccaughey, Concomitant administration of zoster and pneumococcal vaccines in adults ???60 years old, Human Vaccines, vol.6, issue.11, 2008.
DOI : 10.4161/hv.6.11.12852

S. Cook and D. Flaherty, Review of the Persistence of Herpes Zoster Vaccine Efficacy in Clinical Trials, Clinical Therapeutics, vol.37, issue.11, pp.2388-2397, 2015.
DOI : 10.1016/j.clinthera.2015.09.019

. Oxman, Vaccination against Herpes Zoster and Postherpetic Neuralgia, The Journal of Infectious Diseases, vol.197, issue.s2, pp.228-236, 2008.
DOI : 10.1086/522159

. Schmader, «Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the ShortTerm Persistence Substudy» Clinical Infectious Diseases, pp.1320-1328, 2012.

V. Morrison, «Long-term Persistence of Zoster Vaccine Efficacy» Clinical Infectious Diseases, pp.900-909, 2015.

R. Baxter, T. Tran, J. Hansen, M. Emery, B. Fireman et al., «Safety of Zostavax?a cohort study in a managed care organization» Vaccine, pp.6636-6677, 2012.

G. Mick, «Evaluation de l'incidence du zona, de la proportion des douleurs postzostériennes , et des coûts associés dans la population française de 50 ans ou plus» Revue d'Epidémiologie et de Santé Publique, pp.393-401, 2010.

T. Szucs and A. Pfeil, A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination, PharmacoEconomics, vol.48, issue.6 Suppl., pp.125-136, 2013.
DOI : 10.1007/s40273-012-0020-7

N. Ferahta, Les vaccins contre le zona??: efficacit??, s??curit??, et rapport co??t/b??n??fices, La Presse M??dicale, vol.45, issue.2, 2015.
DOI : 10.1016/j.lpm.2015.10.015

X. Bresse, L. Annemans, E. Préaud, K. Bloch, G. Duru et al., Vaccination against herpes zoster and postherpetic neuralgia in France: a cost???effectiveness analysis, Expert Review of Pharmacoeconomics & Outcomes Research, vol.13, issue.3, pp.393-406, 2013.
DOI : 10.1586/erp.13.19

M. Najafzadeh, C. Marra, E. Galanis, and D. Patrick, «Cost effectiveness of herpes zoster vaccine in Canada» Pharmacoeconomics, pp.991-1004, 2009.

. Schmader, Effect of a Zoster Vaccine on Herpes Zoster-Related Interference with Functional Status and Health-Related Quality-of-Life Measures in Older Adults, Journal of the American Geriatrics Society, vol.58, issue.9, pp.1634-1641, 2010.
DOI : 10.1111/j.1532-5415.2010.03021.x

P. Loulergue and O. Launay, Vaccination contre le zona, Journal des Anti-infectieux, vol.17, issue.3, pp.115-119, 2015.
DOI : 10.1016/j.antinf.2015.07.004

M. J. Levin, Immune senescence and vaccines to prevent herpes zoster in older persons, Current Opinion in Immunology, vol.24, issue.4, pp.494-500, 2012.
DOI : 10.1016/j.coi.2012.06.002

. Leroux-roels, «A Phase 1/2 Clinical Trial Evaluating Safety and Immunogenicity of a Varicella Zoster Glycoprotein E Subunit Vaccine Candidate in Young and Older Adults» The Journal of Infectious Diseases, pp.1280-90, 2012.

R. Chlibek, Safety and Immunogenicity of an AS01-adjuvanted Varicella-zoster Virus Subunit Candidate Vaccine Against Herpes Zoster in Adults >=50 Years of Age, Journal of Infectious Diseases, vol.208, issue.12, pp.1953-61, 2013.
DOI : 10.1093/infdis/jit365

H. Lal, M. D. Anthony, and L. , Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults, New England Journal of Medicine, vol.372, issue.22, pp.2087-96, 2015.
DOI : 10.1056/NEJMoa1501184

A. Edward and . Stadtmauer, «A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients» Blood, pp.2921-2929, 2014.

M. Elchonon and . Berkowitz, «Safety and Immunogenicity of an Adjuvanted Herpes Zoster Subunit Candidate Vaccine in HIV-Infected Adults: A Phase 1/2a Randomized, Placebo- Controlled Study» The Journal of Infectious Diseases, pp.1279-87, 2015.